HK Stock Market Move | Hans Ai Tai-B (03378) rebounds nearly 6%, innovative drug HX111 approved for clinical trials by the National Medical Products Administration.

Hansoh Pharmaceutical Group (03378) rebounded by nearly 6%, rising to 5.12% by the time of publication to 18.08 Hong Kong dollars, with a turnover of 10.4874 million Hong Kong dollars. On the news front, Hansoh Pharmaceutical announced that its innovative drug injection HX111 has been approved by the China National Medical Products Administration for clinical trials in China. HX111 is a pioneering OX40-targeted antibody-drug conjugate (ADC). Preclinical studies have shown that OX40 is overexpressed in several malignant tumors compared to normal tissues, making it a suitable target for ADC. In addition, HX111 is the third pioneering molecule to be advanced to clinical development by the company following HX009 and HX044's two FIC bispecific antibody therapies. The company will continue its efforts to bring more novel FIC drugs through clinical development and eventually to market.